A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

October 20, 2027

Study Completion Date

October 20, 2027

Conditions

Lung Cancer

Interventions

DRUG

AMG 510

Given by IV

DRUG

Cisplatin

Given by IV

DRUG

Carboplatin

Given by IV

DRUG

Pemetrexed

Given by IV

Trial Locations (2)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

M D Anderson Cancer Center, Houston